Top Page
Opyl Ltd.
(Sydney:PKY)
Opyl Ltd. (PKY) vs. iShares MSCI Australia ETF (EWA)
Opyl Ltd. Business Overview & Revenue Model
Opyl Ltd. Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Opyl Ltd. Technical Analysis
Opyl Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$10.57M | -1.14 | ― | ― | -40.05% | -49.57% | |
44 Neutral | AU$15.55M | -5.21 | ― | ― | 241.34% | 44.19% | |
43 Neutral | AU$78.49M | -11.01 | ― | ― | ― | ― | |
41 Neutral | AU$4.99M | -5.70 | ― | ― | -9.90% | 34.07% | |
35 Underperform | AU$6.52M | -1.21 | ― | ― | -67.78% | 37.78% |
Opyl Ltd. Corporate Events
Pathkey.AI Ltd has called a general meeting of shareholders to be held on 28 January 2026 at Allendale Square in Perth, Western Australia, with the formal notice outlining the time, location and purpose of the gathering. The document signals that shareholders will be asked to vote on a series of proposed resolutions detailed in accompanying materials, and encourages them to seek professional advice if unsure how to vote, underscoring the potential significance of the decisions for the company’s governance and strategic direction.
Pathkey.AI Ltd has announced a proposed issue of 188,549,547 ordinary fully paid securities, scheduled for January 23, 2026. This move is intended to raise capital through a placement or other type of issue, potentially impacting the company’s market positioning and offering new opportunities for stakeholders.
Pathkey.AI Ltd has announced the dispatch of offer documents for a non-renounceable pro-rata rights issue, allowing eligible shareholders to purchase one fully paid ordinary share for every four shares held. This offer, aimed at raising up to $920,517, follows a previous placement that raised $2,500,000 from sophisticated investors, and is part of the company’s broader capital raising efforts.
PathKey.AI Ltd has announced the issuance of 19,783,786 fully paid ordinary shares without disclosure to investors under the Corporations Act. The company confirms compliance with relevant provisions of the Corporations Act, and there is no excluded information as per the specified sections, indicating transparency and adherence to regulatory standards.
Pathkey.AI Ltd has announced a new application for the quotation of its securities on the Australian Securities Exchange (ASX). The company is set to quote 19,783,786 fully paid ordinary shares under the ASX code PKY, with the issue date being December 11, 2025. This move is part of a previously announced transaction, and it signifies a strategic step for Pathkey.AI in enhancing its market presence and potentially increasing its shareholder base.
PathKey.AI Ltd has announced an equity raising initiative through a non-renounceable entitlement offer, aiming to raise approximately $920,517. This offer will allow eligible shareholders in Australia and New Zealand to purchase one new share for every four shares they currently hold. The initiative is managed by GBA Capital Pty Ltd, with a management fee of 6% of the raised amount. The company assures that the offer will not lead to any significant change in control, as no investor will be able to acquire more than 20% voting power.
Pathkey.AI Ltd is conducting a non-renounceable rights issue to raise approximately $920,517 by offering one new share for every four existing shares at a price of $0.012 per share. The offer is open to eligible shareholders in Australia and New Zealand from December 12, 2025, to January 5, 2026. This initiative is part of the company’s strategy to strengthen its financial position, though the shares are considered speculative, and the offer document is not a prospectus, thus providing limited information.
Pathkey.ai has announced the issuance of unquoted equity securities, specifically options expiring on August 20, 2028, with an exercise price of $0.015. This move involves the issuance of 1,590,025 securities, which could potentially impact the company’s capital structure and provide additional financial resources for future operations.
Pathkey.AI has announced the issuance of unquoted equity securities, specifically 2,000,000 options expiring on August 20, 2029, with an exercise price of $0.03. This move is part of an employee incentive scheme, indicating the company’s strategy to retain and motivate its workforce, potentially impacting its operational efficiency and market competitiveness.
Pathkey.AI Ltd has announced the appointment of Shannon Robinson as a new director, effective November 28, 2025. As part of her appointment, Robinson will receive 4,000,000 unlisted options with an exercise price of $0.03, expiring on August 20, 2029. This appointment and the associated issuance of options are expected to enhance the company’s leadership structure and potentially influence its strategic direction.
PathKey.AI Ltd announced the results of its Annual General Meeting, where all resolutions were approved by the required majority. The meeting included the adoption of the remuneration report, election and approval of directors, and various approvals related to securities and placement capacities. These approvals are expected to support the company’s strategic initiatives and enhance its governance structure.
Pathkey.AI Ltd has announced a proposed issue of 6,474,138 fully paid ordinary securities, with the proposed issue date set for January 6, 2026. This move indicates the company’s strategy to potentially raise capital or expand its shareholder base, which could impact its market positioning and stakeholder interests.
Pathkey.AI Ltd has announced a proposed issue of securities, with a total of 19,783,786 ordinary fully paid shares to be issued. The proposed issue date is December 8, 2025, and the company has applied for these securities to be quoted on the ASX, indicating a strategic move to raise capital and potentially expand its market presence.
Pathkey.AI Ltd has successfully completed a A$2.5 million placement and launched a A$0.98 million rights issue to accelerate its AI growth strategy. The funds will be used to enhance the company’s AI engine, scale commercial activities, and explore strategic growth opportunities. The company also announced governance changes, including the appointment of Shannon Robinson as Non-Executive Chair and the transition of Damon Rasheed to Executive Director, to support its next phase of growth.
Pathkey.AI Ltd has requested a trading halt on its securities pending a significant announcement regarding a capital raising. This move is intended to allow the company time to consider, plan, and execute the capital raising, which is expected to impact its operations and market positioning by potentially providing additional resources for its AI-driven clinical trial optimization efforts.
Pathkey.AI has entered into a Master Collaboration Agreement with Armstrong Clinical to enhance clinical trial success using AI technology. This partnership aims to integrate Pathkey’s AI platform with Armstrong’s expertise in clinical development, focusing on biotech, pharma, medtech, and academic research organizations globally. The collaboration is expected to improve trial outcomes, reduce development risks, and accelerate the path to market, thereby strengthening Pathkey’s commercial expansion strategy and reinforcing Australia’s reputation as a hub for early-phase clinical research. The partnership promises benefits for sponsors, investors, regulators, and patients by enabling better-designed studies and faster access to effective therapies.
Pathkey.AI Ltd has made significant strides in the September 2025 quarter, transitioning from validation to commercial scale. The company has validated the predictive performance of its TrialKey platform, which accurately forecasts clinical trial outcomes and share price inflection points. Enhancements in AI capabilities have expanded the platform’s application towards drug discovery and compound repurposing. Strategic partnerships have been strengthened, and new leadership appointments have been made to guide the company’s growth. Financial discipline has been maintained, with treasury assets and director-supported funding initiatives providing additional flexibility.
PathKey.AI Ltd has announced its Annual General Meeting (AGM) to be held on November 28, 2025, at Milsons Point, NSW. The meeting will address various resolutions affecting shareholders, who are encouraged to vote by proxy if unable to attend. The notice outlines the voting process, emphasizing the importance of shareholder participation and detailing the procedures for proxy voting, including the roles of proxy holders and the chair in the voting process.
Pathkey.AI Ltd has announced the conversion of financial obligations into shares for its directors, Mr. Antanas Guoga and Mr. Damon Rasheed, subject to shareholder approval. This move involves converting a loan from Mr. Guoga and technical consulting fees for Mr. Rasheed into fully paid ordinary shares, aligning the directors’ interests with shareholders and preserving cash resources. These transactions are in line with ASX Listing Rule 10.11 and reflect the company’s strategic approach to maintaining financial stability while engaging its leadership in its growth trajectory.
Opyl Ltd. has announced a change in its substantial holding status, indicating that it or its associates have ceased to be substantial holders in the company. This change reflects alterations in relevant interests and associations related to voting securities, which could impact the company’s shareholder structure and influence in decision-making processes.
Pathkey.AI Ltd has announced the cessation of Saurabh Jain as a director effective October 21, 2025. The final director’s interest notice reveals that Jain holds no registered securities but has indirect interests through Rishi Jain Investments Pty Ltd and Smnaa Investments Pty Ltd, including ordinary shares and director options. This change in directorship may impact the company’s governance and strategic direction, potentially influencing stakeholder confidence and market perception.
Pathkey.AI Ltd has announced the appointment of Paul Niardone as a new director, effective from October 21, 2025. As part of his appointment, Niardone will receive 2,000,000 unlisted options with an exercise price of $0.03, expiring on August 20, 2029. This move is expected to strengthen the company’s leadership and potentially impact its strategic direction, offering stakeholders insights into the company’s future plans and governance.
Pathkey.AI has announced the cessation of 3,333,333 performance rights due to the lapse of conditional rights that were not met or became incapable of being satisfied. This announcement may impact the company’s issued capital and could have implications for stakeholders regarding the company’s operational strategies and financial planning.
PathKey.AI Ltd announced the resignation of Mr. Saurabh Jain as Executive Chairman and Director due to his other growing commitments. Mr. Jain played a crucial role in the company’s transformation and commercialization of its AI platform, TrialKey. He will remain involved as a shareholder and advocate. Mr. Damon Rasheed, the company’s Chief Technology Officer and founder of TrialKey, has been appointed as the new Executive Chairman, ensuring continuity in leadership and strategy. Additionally, Mr. Paul Niardone has been appointed as a Non-Executive Director, bringing extensive experience in equity capital markets and strategic expansion.
Pathkey.AI Ltd announced that its TrialKey platform continues to demonstrate strong predictive capabilities in identifying clinical trials with above-average success probabilities. In September 2025, four new inflection events were observed, with an average share price change of +43.6% from TrialKey observation to post-readout inflection. The company is actively monitoring eleven programs with an average return of 16.7% on stocks yet to report outcomes. These insights are being utilized across various sectors, reinforcing the platform’s value in improving clinical trial success predictions.
Pathkey.AI Ltd has announced that its Annual General Meeting (AGM) will take place on November 26, 2025, with the re-election of Directors as a key agenda item. The deadline for director nominations is set for October 8, 2025. This meeting is crucial for the company’s governance and strategic direction, impacting its operations and stakeholder engagement.